All GLP-1 medications from licensed 503A compounding pharmacies Browse Products
Telehealth Provider — FDA safety data from public records
Medical weight-loss offering by Noom that combines GLP-1 prescribing with the company's established behavior-change and coaching platform.
Website: noom.com
Data last verified: 2026-04-25
Entity Type
Telehealth Provider
FDA Registration
Not shown
Warning Letters
0
Recalls
0
States Licensed
50
Compounding Status
unknown
Noom Med is best understood as a telehealth front end rather than a manufacturer. Patients usually encounter the brand through online intake, clinician review, subscription billing, fulfillment coordination, and follow-up support, while the medication supply chain sits behind the scenes with partner pharmacies or outsourcing facilities.
Noom Med reports coverage across 50 states, which suggests a relatively broad operating footprint rather than a niche single-state presence. For SEO and user trust, that means the important question is not just "is Noom Med legitimate" but "who is prescribing, who is compounding or dispensing, and what claims is the company making about those medications?"
Telehealth companies can scale quickly because marketing, acquisition, and patient communications are centralized. The tradeoff is that a polished consumer brand can sometimes hide weak transparency around pharmacy sourcing, state licensure details, refill logic, escalation paths, and how the company handles adverse events or billing disputes.
Noom Med occupies a more support-heavy, behavior-first position than many telehealth GLP-1 brands. It is often chosen by users who want medication plus a structured habit-change layer.
The product is built on top of Noom's existing psychology and coaching system rather than as a medication-only offer. That means engagement with the behavior platform is central to the value proposition.
Noom is not the producing pharmacy, so the sourcing questions still revolve around which medication track is being used and which dispensing partners support the program.
Noom can be a poor fit for users who only want low-friction medication access and do not care about coaching or curriculum. Patients should confirm whether they want the support stack they are paying for.
Noom Med is designed around behavior change plus medication, not just prescribing.
Its differentiation is educational structure and coaching intensity.
Patients should compare its support-heavy model against lighter-touch competitors before enrolling.
No FDA warning letters are currently shown in this profile.
No recall events are currently shown in the FDA enforcement data surfaced here.
No direct FDA establishment registration record is displayed on this page.
The page shows an operating footprint of 50 states.
Noom Med does not appear in this profile as a directly FDA-registered drug establishment. That is common for telehealth platforms because they usually operate as prescriber and logistics layers while medications are sourced through partner pharmacies or outsourcing facilities.
We did not find FDA warning letters for Noom Med in this profile. That is better than the alternative, but it is not a blanket endorsement. A clean warning-letter record only tells you that this page is not currently surfacing a published FDA warning letter tied to the entity.
No recall events are shown for Noom Med here. For consumers, that lowers one category of concern, but it still does not replace verification of sourcing, labeling, temperature handling, and pharmacy quality controls.
This profile does not currently show a meaningful adverse-event dataset for Noom Med. In practice, that usually means readers should lean more heavily on registration, recalls, warning letters, and pharmacy-partner transparency when evaluating risk.
No direct FDA establishment registration record is shown in this profile for Noom Med. For telehealth companies, that is often expected because the brand may coordinate care while external pharmacies or outsourcing facilities handle compounding or dispensing. Readers should verify the underlying pharmacy partner rather than relying on the consumer brand alone.
No FDA warning letters are currently shown for Noom Med in this profile. That is helpful context, but users should still verify current marketing claims, pharmacy sourcing, and how the company describes compounded medications.
No recalls are currently displayed for Noom Med in the openFDA enforcement data surfaced on this page. That lowers one obvious risk signal, but it should not be treated as proof that all products, batches, or fulfillment practices are problem-free.
Source: openFDA Drug Enforcement API
This profile does not currently show a meaningful adverse-event summary for Noom Med. When that dataset is absent, readers should lean more on the documented public record around registration, recalls, warning letters, and pharmacy-partner transparency.
Source: FDA Adverse Event Reporting System (FAERS). Adverse event reports do not establish causation.
Which pharmacy or outsourcing facility is actually filling Noom Med prescriptions, and can you name it before checkout?
What does Noom Med tell patients about compounded versus FDA-approved products, and does that language avoid implying equivalence or approval where it does not exist?
How does Noom Med handle dose escalations, refill delays, refunds, cancellations, and temperature-sensitive shipping problems?
If a patient has a side effect or receives a product-quality concern, what is the human escalation path and how quickly does Noom Med respond?
Can Noom Med provide lot-level documentation, pharmacy details, and a clear explanation of what safety checks happen before medication is dispensed?
These related profiles are useful for searchers comparing Noom Med against adjacent providers or pharmacies. Reading similar pages side by side usually reveals whether a concern is unique to one company or common across this category.
This profile organizes public-source safety signals for Noom Med, including FDA registration status, warning letters, recalls, and any adverse event summary data available in the dataset.
A company can appear relatively clean here and still deserve more diligence, because absence of a warning letter or recall is not the same as proof of quality.
For telehealth provider pages especially, readers should distinguish between the consumer-facing brand and the pharmacy or facility that actually handles medication production or dispensing.
Use these links to validate the key claims in this profile and to separate the consumer-facing brand story from the underlying regulatory record.
Noom Med official program page
Supports the behavior-change-plus-medication model described in this profile.
Noom official website
Primary company website used to verify Noom's broader platform identity and consumer-facing weight-loss positioning.
FormBlends partners with licensed 503A compounding pharmacies. Every compound is third-party tested with certificates of analysis.
Learn MoreDisclaimer: This page aggregates publicly available data from the FDA, state pharmacy boards, and other government sources. It is provided for informational purposes only and does not constitute medical or legal advice. FDA registration does not imply FDA approval or endorsement. The absence of warning letters or recalls does not guarantee safety or quality. Always consult your healthcare provider before making decisions about medications. Data may not reflect the most current status. Last updated: 2026-04-25.
503A vs 503B pharmacies
Understanding the FDA oversight difference.
How to read a Certificate of Analysis
What every CoA should include and red flags to watch for.
What FDA registration actually means
Registration vs approval: the distinction most people miss.
Choosing a compounding pharmacy
What to verify before you fill your first prescription.
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.
We do not currently have FDA registration data for Noom Med. This may mean the company operates under a different entity name or is regulated at the state level.
We have not found any FDA warning letters issued to Noom Med in our records. This page is updated regularly as new FDA data becomes available.
We have not found any recalls associated with Noom Med in the openFDA enforcement database.
Noom Med is categorized in this profile as a telehealth provider. That distinction matters because a telehealth brand, a 503A pharmacy, and a 503B outsourcing facility operate under different regulatory expectations.
No. A clean profile means we are not currently surfacing certain FDA signals like warning letters or recalls for Noom Med. It does not guarantee product quality, customer-service quality, or future regulatory compliance.
Patients should verify who is prescribing, which pharmacy or outsourcing facility is actually fulfilling the medication, what the company says about compounded versus FDA-approved products, and how billing, cancellations, and side-effect escalation are handled.